Combination of HLA-A24, -DQA1*03, and -DR9 Contributes to Acute-Onset and Early Complete β-Cell Destruction in Type 1 Diabetes
Longitudinal Study of Residual β-Cell Function
- 1Department of Endocrinology and Metabolism, Toranomon Hospital, Tokyo, Japan
- 2Okinaka Memorial Institute for Medical Research, Tokyo, Japan
- 3Department of Molecular Life Science, Division of Molecular Medical Science and Molecular Medicine, Tokai University Graduate School of Medicine, Kanagawa, Japan
- Address correspondence and reprint requests to Koji Nakanishi, MD, PhD, Department of Endocrinology and Metabolism, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan. E-mail: koji01{at}toranomon.gr.jp
Abstract
To elucidate the genetic factors contributing to heterogeneity of the rate of β-cell destruction in type 1 diabetes, we investigated the relationship between the time course of complete β-cell loss and HLA class I and II alleles. HLA allele frequencies were also examined among subgroups classified by the mode of onset. The subjects were 266 type 1 diabetic patients (among whom 196 patients were studied longitudinally) and 136 normal control subjects. Earlier complete loss of β-cell function was observed in patients who possessed both HLA-A24 and HLA-DQA1*03 and in patients who had HLA-DR9, compared with those without these HLA alleles (P = 0.0057 and 0.0093, respectively). Much earlier complete β-cell loss was observed in the patients who possessed all of HLA-A24, -DQA1*03, and -DR9 compared with the remaining patients (P = 0.0011). The combination of HLA-A24, -DQA1*03, and -DR9 showed a higher frequency in acute-onset than slow-onset type 1 diabetes (P = 0.0002). In contrast, HLA-DR2 was associated with a slower rate of progression to complete β-cell loss. These results indicate that the combination of HLA-A24, -DQA1*03, and -DR9 contributes to the acute-onset and early complete β-cell destruction, whereas HLA-DR2 has a protective effect against complete β-cell loss in type 1 diabetes.
- ADA, American Diabetes Association
- CPR, C-peptide response
- LADA, latent autoimmune diabetes of adults
- RFLP, restriction fragment–length polymorphism
Footnotes
-
- Accepted February 27, 2006.
- Received August 16, 2005.
- DIABETES














